Was that for me or Aaron?
I did not read all of the prospectus. Does it require uplisting within a certain timeframe? Inquiring minds want to know.
Lee, it all depends on uplisting and ASCO data.
They do not report on efficacy, even if a signal is there as with the lady with ovarian cancer. You could pick out of earlier data they released, but they have not given any clues recently. So no uplisting and no data = continued languishing.
If they uplist OR put data out...it will move. But not until then. I think it will take only one of those two catalysts.
I have to wonder is Aspire put some pressure on them somehow. Why throw in $30 million if you don't expect some return on that investment?
Aspire capital is not stupid.
If uplisting happens I'll be impressed...and stunned. They've been talking about it for 2 years.
Is it possible that part of the Aspire deal was "we'll do this if you uplist in x-number of days"?
What is not needed is "news".
What is needed is news of developments such an uplist, or more hard data on K or B, or for a new trial to open.
Lots of potential here...and very quiet. Bet they were sidetracked for a while with the Aspire deal.
Perhaps the silence means they are working hard on more important issues than keeping me updated...that would be a good use of time!
I doubt Aspire would willingly waste $30 million on a huge risk. Most companies like Aspire get plenty of information on the drugs well in advance. I thought the financing was a huge positive. They need to accelerate the pace of their trials though. They are going a bit slow.
Right now its just a waiting game but that does mean interest will be low.
At this point I have to agree with ctix.bigscam
CTIX appears to have very little interest. Credibility is on the fence. Lets hope for a good conference later this month and no more "cohort updates" as that is largely fluff.
$30 million from Aspire. Didn't read the details in the prospectus to see how all of this gets priced but it seems they paid 3.16 or today's closing price for a little under 10 million shares.
Why no comments on efficacy? I want to hear about results! I know it is phase I but you can see results in many of these trials.
I was one of those who has said "give us real data", etc...
This would be a big step in that direction and it sounds likes it true. Nice pickup on your part.
props to Maz for putting it out there.
Ride the wave until april guys. At least he put out a solid prediction. I too see the issues. Make sure you have a good stop loss around that time. Best of luck guys.
Every time it goes below $4 expect a similar press release. Essentially a nothingburger...."we are planning x or y". Well, shut up and do it or give us a release detailing results, not plans.
....repeat your synopsis of what you think will happen over he next two to six months. You seem to be very prescient and point out some glaring issues that others gloss over. Thanks for your input.
He is pumping now that the share price dipped under $4. He does want it listed so they want to boost the price.
This is a ridiculous release. Give us the data on the whole group. Many early studies will see a few responders but then the whole cohort will not show benefit. Did she have wild type or mutated P53? What about the others?
Give us real information next time not an anecdote to pump up your stock.
Not sure if Aruda is dumping...might make sense for them to hold it.
Still...that momentous December was followed by a "thud" in January! I think Leo or whoever was schooled by the market. No more empty promises. There is no "deal" in the works; these guys have to get a real board and act like a company before more serious interest from funds, the market in general, or big pharma comes along.
Admittedly, the pipeline looks good. So why don't they act like a real company? Leo? Krishna? Bueller? Bueller? Anyone?